ESR1 and breast carcinoma: A particularly aggressive and therapeutically challenging subtype of BC is triple-negative breast cancer (TNBC), which constitutes 10–15% of all breast cancer cases and is defined by the absence of estrogen receptor α (ERα), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2) expression [5,6].